Cereno Scientific and OCT signs contract for the conduct of a phase II study in patients undergoing knee replacement
Cereno Scientific and OCT Group LCC (‘’OCT’’) have previously signed a Letter of Intent regarding their collaboration to conduct a phase II study to investigate the antithrombotic effects of Cereno’s candidate drug CS1. The two companies have now reached a definitive agreement and set out the framework for the planned phase II study. Applications to regulatory authorities to conduct the study are expected to be submitted in the fourth quarter of 2018.“The planned phase II study will be the second clinical study with CS1. The study is based on solid results from preclinical studies and a